Eugene Schneider - 12 Jan 2024 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)

Reporting relationship: EVP, Chf Clinical Develop Ofcr
Issuer ticker: IONS
Reported as of: 12 Jan 2024
Net transaction value: -$167,199
SEC form: 4
Accepted by SEC: 17 Jan 2024, 20:51:55 UTC
Prior SEC filing: 04 Jan 2024
Next SEC filing: 18 Jan 2024
Source filing: View source filing
Reporting owner signature: By: Patrick R. O'Neil, attorney-in-fact For: Eugene Schneider

Key filing fact

Eugene Schneider filed Form 4 for IONIS PHARMACEUTICALS INC (IONS) on 17 Jan 2024.

Key facts

This page summarizes Eugene Schneider's Form 4 filing for IONIS PHARMACEUTICALS INC (IONS).
5 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 17 Jan 2024, 20:51.

Change

Previous filing in this sequence was filed on 04 Jan 2024.
Current net transaction value: -$167,199.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IONS transaction

Common Stock

Options Exercise

Transaction value: $260,800
Shares: +8,000
Change %: +21%
Price: $32.60
Shares after: 46,170
Date: 12 Jan 2024
Ownership: Direct

IONS transaction

Common Stock

Sale

Transaction value: $427,999
Shares: -8,000
Change %: -17%
Price: $53.50
Shares after: 38,170
Date: 12 Jan 2024
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IONS transaction Derivative

Non-Qualified Stock Option (right to buy)

Options Exercise

Transaction value: $0
Shares: -8,000
Change %: -25%
Price: $0.000000
Shares after: 24,265
Date: 12 Jan 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,000
Exercise price: $32.60

IONS transaction Derivative

Performance Restricted Stock Units

Award

Transaction value: $0
Shares: +17,000
Change %: +64%
Price: $0.000000
Shares after: 43,437
Date: 15 Jan 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 17,000
Exercise price: $0.000000
Footnotes: F1, F2

IONS transaction Derivative

Restricted Stock Unit

Award

Transaction value: $0
Shares: +20,400
Change %: +51%
Price: $0.000000
Shares after: 60,470
Date: 15 Jan 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,400
Exercise price: $0.000000
Footnotes: F3, F4, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 5 footnotes

Footnote F1

Grant to reporting person of Performance Restricted Stock Units (PRSUs) under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

Footnote F2

The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated.

Footnote F3

Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

Footnote F4

Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

Footnote F5

Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.